Technologies related to Cancer

Fluorescent Primer(s) Creation for Nucleic Acid Detection and Amplification
Ref: E-252-2013-0 | Updated: Mar 9, 2020
Photoinduced Electron Transfer Fluorescent Primer for Nucleic Acid Amplification
Ref: E-292-2013-0 | Updated: Mar 9, 2020
Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73)
Ref: E-132-2018-0 | Updated: Aug 9, 2019
A Novel Reagent for Labeling PET Tracers at Trifluoromethyl Groups
Ref: E-259-2016-0 | Updated: Jun 28, 2018
Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites
Ref: E-206-2017-0 | Updated: May 23, 2018
CXCR1 - Human IL-8 Receptor cDNA
Ref: B-004-1995-0 | Updated: Dec 4, 2017
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-120-2013-0 | Updated: Oct 2, 2017
Evans Blue Dye Derivatives for Serum Albumin Labeling
Ref: E-099-2015-0 | Updated: Aug 24, 2017
Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs
Ref: E-162-2013-0 | Updated: Aug 31, 2017
Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
Ref: E-059-2004-0 | Updated: Jul 6, 2017
Engineered Anthrax Toxin Variants that Target Cancer
Ref: E-246-2012-0 | Updated: Jul 6, 2017
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Ref: E-293-1999-0 | Updated: Jul 6, 2017
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7
Ref: E-036-2015-0 | Updated: May 17, 2017
Tg(MMTV-Cre)#Mam Mouse Model for Developmental Biology, Hepatology, and Oncology Studies
Ref: E-113-2012-0 | Updated: Apr 17, 2017
Non-invasive Pan-Cancer Detection Method
Ref: E-177-2015-0 | Updated: Nov 8, 2016
Bag6 Polyclonal Antibodies That Recognize Human Bag6 Protein
Ref: E-077-2015-0 | Updated: Sep 8, 2016
Long Acting Therapeutic Conjugates with Evans Blue
Ref: E-143-2015-0 | Updated: Jun 27, 2016
Murine Cell Models for Metastatic Squamous Cell Carcinoma
Ref: E-213-2016-0 | Updated: Jun 22, 2016
Metallic Nanoparticles for Photothermal Therapy
Ref: E-158-2015-0 | Updated: Jan 4, 2016
SIRT1 KO Human Cell Lines Generated by CRISPR/Cas9-mediated DNA Editing
Ref: E-184-2015-0 | Updated: Nov 30, 2015
A Genetic System in Yeast for Functional Identification of Human p53 Mutations
Ref: E-183-1999-0 | Updated: May 18, 2018
Genome Wide DNase I Hypersensitive Sites Detection in Formalin-Fixed Paraffin-Embedded Single Cells
Ref: E-254-2014-0 | Updated: Aug 17, 2015
Rabbit Antisera to Various Matrix, Matricellular, and Other Secreted Proteins
Ref: E-135-2008-0 | Updated: May 7, 2018
Modified AAV5 Vectors for Enhanced Transduction and Reduced Antibody Neutralization
Ref: E-097-2015-0 | Updated: May 1, 2019
A Novel Adeno-Associated Virus for Gene Therapy
Ref: E-175-2015-0 | Updated: May 1, 2019
Boron Amino Acid Mimetics for PET Imaging of Cancer
Ref: E-135-2015-0 | Updated: Jun 29, 2015
Device for Selective Partitioning of Frozen Cellular Products
Ref: E-173-2009-0 | Updated: Jun 29, 2015
CXCR4 Reduction Leads to Enhancement of Engraftment of Hematopoietic Stem Cells
Ref: E-173-2014-0 | Updated: Jul 1, 2015
T Cell-Based Adoptive Transfer Immunotherapy for Polyomavirus-Associated Pathologies
Ref: E-166-2014-0 | Updated: Sep 12, 2017
Highly Sensitive Tethered-Bead Immune Sandwich Assay
Ref: E-188-2014-0 | Updated: Jan 13, 2015
Octopod (8-Pointed Star) Iron Oxide Nanoparticles Enhance MRI T2 Contrast
Ref: E-314-2013-0 | Updated: Jun 5, 2018
Ultra-sensitive Diagnostic Detects fg/mL-pg/mL Pathogen/Disease Protein by Visual Color Change
Ref: E-167-2014-0 | Updated: Sep 17, 2015
A Current Amplifier for Local Coil Pre-amplification of NMR/MRI Signals
Ref: E-122-2014-0 | Updated: May 18, 2018
Use of Small Molecules to Treat PARP1-deficient Cancers
Ref: E-039-2014-0 | Updated: Dec 16, 2015
A Novel X-ray Grating to Enhance Phase Contrast Imaging
Ref: E-114-2013-0 | Updated: May 18, 2018
A Novel Demodulation System in X-ray Imaging
Ref: E-113-2013-0 | Updated: May 18, 2018
Novel Epstein-Barr Virus Vaccines
Ref: E-531-2013-0 | Updated: Dec 17, 2015
Human iPSC-Derived Mesodermal Precursor Cells and Differentiated Cells
Ref: E-342-2013-0 | Updated: May 14, 2018
Methods for the Simultaneous Detection of Multiple Analytes
Ref: E-142-2013-0 | Updated: Feb 6, 2014
Automated Microscopic Image Acquisition, Compositing and Display Software Developed for Applied Microscopy/Cytology Training and Analysis
Ref: E-228-2013-0 | Updated: Feb 6, 2014
Methods of Retaining Methylation Pattern Information in Globally Amplified DNA
Ref: E-243-2013-0 | Updated: Feb 6, 2014
Therapeutic, Bifunctional Janus Microparticles with Spatially Segregated Surface Proteins and Methods of Production
Ref: E-457-2013-1 | Updated: Jan 28, 2014
Use of Detector Response Curves to Optimize Settings for Mass Spectrometry
Ref: E-157-2013-0 | Updated: Jan 20, 2014
Signatures of Genetic Control in Digestive and Liver Disorders
Ref: E-349-2013-0 | Updated: Nov 18, 2015
Generation of Artificial Mutation Controls for Diagnostic Testing
Ref: E-255-2013-0 | Updated: May 24, 2016
Human Melanoma Metastasis Cell Lines Harboring Bcl-2-Like Protein 12 (BCL2L12) Mutations
Ref: E-145-2012-0 | Updated: May 8, 2018
Pyruvate Kinase M2 Activators for the Treatment of Cancer
Ref: E-298-2011-1 | Updated: May 7, 2018
Highly Potent and Selective Deubiquitinating Enzyme Inhibitor
Ref: E-043-2013-0 | Updated: Nov 18, 2015
mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis
Ref: E-257-2012-0 | Updated: May 8, 2018
Mutations in the G Protein Coupled Receptor (GPCR) Gene Family in Melanoma
Ref: E-244-2010-0 | Updated: May 8, 2018
Human Melanoma Metastasis Cell Lines Harboring GRM3 Mutations
Ref: E-029-2012-0 | Updated: May 8, 2018
Human Melanoma Metastasis Cell Lines Harboring MITF Mutations
Ref: E-023-2012-0 | Updated: May 8, 2018
Human Melanoma Metastasis Cell Lines Harboring TRRAP, GRIN2A, and PLCB4 Mutations
Ref: E-024-2012-0 | Updated: May 8, 2018
New Targeted Therapy for Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
Ref: E-060-2011-0 | Updated: Sep 10, 2012
A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy
Ref: E-140-2008-1 | Updated: Jun 13, 2012
Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Cancer
Ref: E-177-2012-0 | Updated: Apr 15, 2016
Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling
Ref: E-073-2012-0 | Updated: Feb 18, 2016
UTX LoxP Mouse Model for Oncology Research
Ref: E-118-2012-0 | Updated: Feb 23, 2016
Sirt1 Knockout (Sirt1tm1.1Cxd) Mouse Model for Oncology and Metabolism Studies
Ref: E-120-2012-0 | Updated: May 14, 2018
Stat1LoxP (Stat1 tm1Mam ) Mouse Model for Oncology and Immunology Studies
Ref: E-111-2012-0 | Updated: Mar 10, 2014
Small-Molecule Inhibitors of Human Galactokinase for the Treatment of Galactosemia and Cancers
Ref: E-240-2011-0 | Updated: Apr 20, 2016
Model Cell Lines With and Without AKT1 Mutations Derived from Proteus Syndrome Patients
Ref: E-033-2012-0 | Updated: Oct 13, 2015
Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors
Ref: E-276-2011-0 | Updated: Apr 21, 2016
Transgenic Human Interleukin-21 Mouse Model
Ref: E-231-2010-0 | Updated: Jan 18, 2012
Biomarkers for Cancer-Related Fatigue and Their Use in the Management of Such Fatigue (CRF)
Ref: E-280-2010-0 | Updated: Nov 18, 2015
Platform Technology Using Ubiquitin to Improve the Delivery and Efficacy of Cytosolic Targeted Toxins
Ref: E-150-2011-0 | Updated: Sep 29, 2011
mGluR5 Tumor Mouse Model
Ref: E-123-2010-0 | Updated: Sep 29, 2011
TRRAP and GRIN2A Mutations for the Diagnosis and Treatment of Melanoma
Ref: E-013-2011-0 | Updated: May 8, 2018
Mouse Model and Derived Cells That Hypersecrete Leukemia Inhibitory Factor (LIF)
Ref: E-175-2011-0 | Updated: May 3, 2016
NAG-1 Transgenic Mouse Model
Ref: E-093-2011-0 | Updated: Apr 17, 2013
Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications
Ref: E-012-2011-0 | Updated: Sep 9, 2020
Pyruvate Kinase M2 Activators for the Treatment of Cancer
Ref: E-120-2010-0 | Updated: Mar 12, 2015
ERBB4 Mutations Identified in Human Melanoma Metastasis Cell Lines (2690, 2379, 2197, 2183, 2535, 2645, 1770, 2359, 2238, 2319, 2190)
Ref: E-229-2010-0 | Updated: May 8, 2018
Isocitrate Dehydrogenase 1 (IDH1) R132 Mutation Human Melanoma Metastasis Cell Line
Ref: E-232-2010-0 | Updated: May 8, 2018
Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders
Ref: E-291-2009-0 | Updated: Nov 26, 2010
Mouse Anti-Mouse CXCL9 (Mig) Monoclonal Antibodies
Ref: E-198-2009-0 | Updated: Oct 12, 2010
Method of Producing Immortalized Primary Human Keratinocytes for HPV Investigation, Testing of Therapeutics, and Skin Graft Generation
Ref: E-055-2009-0 | Updated: Sep 21, 2015
Diagnostic Biomarker of Metastasis for Improved Clinical Management of Head and Neck Cancer
Ref: E-300-2008-0 | Updated: May 8, 2018
Mutations of the ERBB4 Gene in Melanoma
Ref: E-272-2008-0 | Updated: May 8, 2018
Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21
Ref: E-250-2005-0 | Updated: May 16, 2018
Novel Method of Treating Cancer Using Ixolaris
Ref: E-148-2009-0 | Updated: Jun 16, 2010
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
Ref: E-326-2008-0 | Updated: May 5, 2009
Prevention of Head and Neck Cancer Using Rapamycin and Its Analogs
Ref: E-302-2008-0 | Updated: May 8, 2018
Mouse Monoclonal Antibodies to MAD1, a Human Spindle Assembly Checkpoint Protein for Maintaining Chromosomal Segregation
Ref: E-119-2003-0 | Updated: Jan 19, 2016
Prostatic Adenocarcinoma Cells Expressing or Lacking the Tumor Suppressor Gene PTEN
Ref: E-292-2008-0 | Updated: Oct 1, 2008
Vitamin D Receptor Antagonists for Treating Breast Cancer
Ref: E-213-2001-2 | Updated: Sep 1, 2008
Rapid and Sensitive Detection of Nucleic Acid Sequence Variations
Ref: E-071-2003-0 | Updated: Jul 1, 2008
The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases
Ref: E-096-2000-0 | Updated: May 1, 2008
Method of Inducing Memory B Cell Development and Terminal Differentiation
Ref: E-120-2003-2 | Updated: May 1, 2008
A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency
Ref: E-268-2007-0 | Updated: Nov 9, 2015
Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers
Ref: E-208-2007-0 | Updated: Jun 14, 2010
Hybridoma C4H3, Monoclonal Antibody to a Specific Peptide-MHC Class II Complex
Ref: E-021-2008-0 | Updated: Sep 19, 2017
Treatment of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists
Ref: E-161-2007-0 | Updated: Sep 1, 2007
Probe Set Global Optimization
Ref: E-332-2005-0 | Updated: Aug 1, 2007
Methods for Expression and Purification of Immunotoxins
Ref: E-043-1997-2 | Updated: Nov 9, 2015
Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms
Ref: E-117-2006-0 | Updated: Jun 1, 2007
Methods of Inducing Immune Tolerance Using Immunotoxins
Ref: E-012-1991-0 | Updated: Nov 9, 2015
Human Cancer Therapy Using Engineered Anthrax Lethal Toxin
Ref: E-070-2007-2 | Updated: Jun 16, 2010
Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy
Ref: E-183-2004-1 | Updated: Sep 30, 2010
ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation
Ref: E-347-2004-1 | Updated: Jun 1, 2010


Subscribe to Technologies related to Cancer